Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin.

Priskorn M, Sidhu JS, Larsen F, Davis JD, Khan AZ, Rolan PE.

Br J Clin Pharmacol. 1997 Aug;44(2):199-202.

3.

Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

Almeida L, Falc√£o A, Vaz-da-Silva M, Nunes T, Santos AT, Rocha JF, Neta C, Macedo T, Fontes-Ribeiro C, Soares-da-Silva P.

Eur J Clin Pharmacol. 2008 Oct;64(10):961-6. doi: 10.1007/s00228-008-0534-2.

PMID:
18679669
4.

Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

He YL, Sabo R, Riviere GJ, Sunkara G, Leon S, Ligueros-Saylan M, Rosenberg M, Dole WP, Howard D.

Curr Med Res Opin. 2007 May;23(5):1131-8.

PMID:
17519080
5.

Absence of a pharmacokinetic interaction between etanercept and warfarin.

Zhou H, Patat A, Parks V, Buckwalter M, Metzger D, Korth-Bradley J.

J Clin Pharmacol. 2004 May;44(5):543-50.

PMID:
15102876
6.

Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.

Wright DH, Herman GA, Maes A, Liu Q, Johnson-Levonas AO, Wagner JA.

J Clin Pharmacol. 2009 Oct;49(10):1157-67. doi: 10.1177/0091270009341653.

PMID:
19783710
7.

Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.

Schwartz JI, Dunbar S, Yuan J, Li S, Gipson A, Rosko K, Johnson-Levonas AO, Lasseter KC, Addy C, Stoch AS, Wagner JA.

Adv Ther. 2008 Nov;25(11):1175-90. doi: 10.1007/s12325-008-0116-9.

PMID:
18989636
8.
9.

Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.

Malhotra B, Alvey C, Gong J, Li X, Duczynski G, Gandelman K.

Br J Clin Pharmacol. 2011 Aug;72(2):257-62. doi: 10.1111/j.1365-2125.2011.03989.x.

10.

Divergent effects of raloxifene HCI on the pharmacokinetics and pharmacodynamics of warfarin.

Miller JW, Skerjanec A, Knadler MP, Ghosh A, Allerheiligen SR.

Pharm Res. 2001 Jul;18(7):1024-8.

PMID:
11496940
11.

Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin.

Schwartz JI, Liu F, Stroh M, Gipson A, Johnson-Levonas AO, Lasseter KC, Lai E, Wagner JA.

Am J Ther. 2009 May-Jun;16(3):215-23. doi: 10.1097/MJT.0b013e31818f9c68.

PMID:
19454860
12.

Effect of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics and pharmacodynamics of steady-state warfarin.

Kirby LC, Johnson BM, Adams LM, Eberwein DJ, Zhang K, Murray SC, Lates CD, Blum RA, Morris SR.

J Clin Pharmacol. 2010 May;50(5):566-75. doi: 10.1177/0091270009346965.

PMID:
20220045
13.

Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin.

Kong AN, Tomasko L, Waldman SA, Osborne B, Deutsch PJ, Goldberg MR, Bjornsson TD.

J Clin Pharmacol. 1995 Oct;35(10):1008-15.

PMID:
8568008
14.
15.

Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ.

Br J Clin Pharmacol. 2004 May;57(5):592-9. Erratum in: Br J Clin Pharmacol. 2004 Jul;58(1):102.

16.

The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol.

Sunkara G, Bigler H, Wang Y, Smith H, Prasad P, McLeod J, Ligueros-Saylan M.

Curr Med Res Opin. 2004 Jan;20(1):41-8.

PMID:
14741071
17.

Effects of duloxetine on the pharmacodynamics and pharmacokinetics of warfarin at steady state in healthy subjects.

Chappell J, He J, Knadler MP, Mitchell M, Lee D, Lobo E.

J Clin Pharmacol. 2009 Dec;49(12):1456-66. doi: 10.1177/0091270009344335.

PMID:
19793910
18.

Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects.

Karim A, Tolbert D, Piergies A, Hubbard RC, Harper K, Wallemark CB, Slater M, Geis GS.

J Clin Pharmacol. 2000 Jun;40(6):655-63.

PMID:
10868317
19.

Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin.

Wade M, Hunt TL, Lai AA.

J Cardiovasc Pharmacol. 2003 Jun;41(6):908-15.

PMID:
12775969
20.

Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin.

Ragueneau-Majlessi I, Levy RH, Meyerhoff C.

Epilepsy Res. 2001 Nov;47(1-2):55-63.

PMID:
11673021
Items per page

Supplemental Content

Support Center